AbCellera Biologics Inc

26 de ago. de 2026, 19:56 UTC

Abcellera Biologics Inc shares are lower today, influenced by declines in the ARK Genomic Revolution ETF and broader genomic sector trends.

25 de ago. de 2026, 23:06 UTC

Abcellera Biologics Inc. shares declined slightly in after-market trading, despite remaining above their 20-day moving average after recent gains.

24 de ago. de 2026, 23:36 UTC

Abcellera Biologics Inc. is rising in after-market trading, fueled by a director's $570,000 insider purchase near its 52-week high, indicating insider confidence.

21 de ago. de 2026, 19:36 UTC

Abcellera Biologics Inc shares are lower today amid broader market pressures. The decline coincides with a drop in U.S. Treasury yields and infrastructure-related assets.

20 de ago. de 2026, 19:16 UTC

Abcellera shares lower amid broader market pressures, influenced by SPDR ETF.

19 de ago. de 2026, 23:02 UTC

Abcellera Biologics Inc shares are higher in after-hours trading, reflecting increased investor interest and social media discussions about the stock's potential at $12.20.

18 de ago. de 2026, 19:56 UTC

Abcellera Biologics Inc shares are lower, influenced by declines in small-cap stocks and rising Treasury yields amid ongoing inflation concerns.

17 de ago. de 2026, 23:06 UTC

Abcellera Biologics Inc shares are lower in after-market trading, following unusual volatility and a decline in the Russell 2000 Index.

14 de ago. de 2026, 19:44 UTC

Abcellera Biologics Inc shares are higher today amid increased call option volume and discussions of insider buying, with the stock trading around $10.50.

13 de ago. de 2026, 19:31 UTC

Abcellera Biologics priced an oversubscribed offering at $9.75 per share, aiming to raise $200 million. Shares are higher since Wednesday's close despite earlier pullback.

12 de ago. de 2026, 20:02 UTC

Abcellera Biologics has launched a $200 million public offering to support its lead program, while shares are advancing during today's trading session.

11 de ago. de 2026, 22:51 UTC

Abcellera Biologics announced a $200 million public offering, contributing to a decline in after-market trading amid investor concerns over potential dilution.

10 de ago. de 2026, 23:06 UTC

Abcellera Biologics reported positive Phase 2 trial results for ABCL635, but shares are lower in after-market hours amid broader market declines.

8 de ago. de 2026, 00:06 UTC

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are trading higher in after-market hours.

7 de ago. de 2026, 23:21 UTC

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

6 de ago. de 2026, 23:06 UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

5 de ago. de 2026, 23:02 UTC

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

3 de ago. de 2026, 19:36 UTC

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

31 de jul. de 2026, 19:33 UTC

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

30 de jul. de 2026, 23:41 UTC

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

29 de jul. de 2026, 23:51 UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.

28 de jul. de 2026, 19:41 UTC

Abcellera Biologics is rising, driven by gains in the Life Sciences Tools & Services sector and positive trends in the antibody therapeutics market.

27 de jul. de 2026, 19:46 UTC

Abcellera Biologics Inc shares are higher, reflecting a modest increase since Friday's close. Broader market gains may influence sentiment in life sciences.

24 de jul. de 2026, 23:46 UTC

Abcellera Biologics Inc shares are higher in after-market hours, showing resilience despite recent challenges in the bond market and declining prices.

22 de jul. de 2026, 20:06 UTC

Abcellera Biologics Inc shares are lower today, reflecting broader market trends amid uncertainty ahead of the Federal Reserve meeting on July 29.

21 de jul. de 2026, 23:06 UTC

Abcellera Biologics shares higher in after-market trading, maintaining strong performance since Tuesday's close, despite being below its 20-day moving average.

20 de jul. de 2026, 23:16 UTC

Abcellera Biologics Inc. shares are roughly flat in after-market trading, remaining about 16.33% below their 20-day moving average.